Since we found that ALDH1A1 and PPP activity influence erythronate levels (Figure 3 and Figure 4), increased erythronate could potentially reflect the overexpression of ALDH1A1 or PPP enzymes, which have been described in other cancers as reflecting poor clinical outcomes [25,26,28,29,36]. This evidence concerns the gene ALDH1A1 and cancer.